State Street
CTMX icon

State Street’s CytomX Therapeutics CTMX Stock Holding History

State Street’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.6M Buy
5,663,408
+522,477
+10% +$2.65M ﹤0.01% 2092
2025
Q4 		$21.9M Buy
5,140,931
+4,495,949
+697% +$17.1M ﹤0.01% 2220
2025
Q3 		$2.06M Buy
644,982
+5,942
+0.9% +$13.4K ﹤0.01% 3330
2025
Q2 		$1.45M Buy
639,040
+318,997
+100% +$514K ﹤0.01% 3404
2025
Q1 		$203K Hold
320,043
– – ﹤0.01% 3821
2024
Q4 		$330K Buy
320,043
+56,400
+21% +$60.7K ﹤0.01% 3734
2024
Q3 		$311K Hold
263,643
– – ﹤0.01% 3705
2024
Q2 		$322K Sell
263,643
-3,833
-1% -$7.63K ﹤0.01% 3675
2024
Q1 		$583K Hold
267,476
– – ﹤0.01% 3606
2023
Q4 		$415K Hold
267,476
– – ﹤0.01% 3690
2023
Q3 		$345K Hold
267,476
– – ﹤0.01% 3764
2023
Q2 		$460K Hold
267,476
– – ﹤0.01% 3709
2023
Q1 		$404K Buy
267,476
+43,500
+19% +$98.3K ﹤0.01% 3814
2022
Q4 		$358K Hold
223,976
– – ﹤0.01% 3881
2022
Q3 		$325K Hold
223,976
– – ﹤0.01% 3935
2022
Q2 		$410K Sell
223,976
-974,706
-81% -$1.87M ﹤0.01% 3909
2022
Q1 		$3.2M Sell
1,198,682
-1,540,862
-56% -$5.92M ﹤0.01% 3384
2021
Q4 		$11.9M Sell
2,739,544
-1,297,393
-32% -$7.6M ﹤0.01% 2824
2021
Q3 		$20.5M Sell
4,036,937
-579,625
-13% -$3.1M ﹤0.01% 2468
2021
Q2 		$29.2M Buy
4,616,562
+1,257,697
+37% +$9.79M ﹤0.01% 2247
2021
Q1 		$26M Buy
3,358,865
+1,308,268
+64% +$10.4M ﹤0.01% 2198
2020
Q4 		$13.4M Sell
2,050,597
-98,657
-5% -$705K ﹤0.01% 2463
2020
Q3 		$14.3M Sell
2,149,254
-46,395
-2% -$344K ﹤0.01% 2235
2020
Q2 		$18.3M Buy
2,195,649
+1,208,701
+122% +$11.2M ﹤0.01% 2075
2020
Q1 		$7.57M Sell
986,948
-2,622
-0.3% -$18.3K ﹤0.01% 2429
2019
Q4 		$8.22M Sell
989,570
-551,119
-36% -$3.72M ﹤0.01% 2618
2019
Q3 		$11.4M Sell
1,540,689
-192,764
-11% -$1.9M ﹤0.01% 2414
2019
Q2 		$19.4M Sell
1,733,453
-361,032
-17% -$3.78M ﹤0.01% 2131
2019
Q1 		$22.5M Buy
2,094,485
+554,535
+36% +$8.2M ﹤0.01% 1959
2018
Q4 		$23.3M Sell
1,539,950
-441,600
-22% -$6.55M ﹤0.01% 1876
2018
Q3 		$36.7M Buy
1,981,550
+269,429
+16% +$6.14M ﹤0.01% 1762
2018
Q2 		$39.1M Buy
1,712,121
+559,163
+48% +$14.3M ﹤0.01% 1648
2018
Q1 		$32.8M Buy
1,152,958
+61,142
+6% +$1.75M ﹤0.01% 1713
2017
Q4 		$23M Buy
1,091,816
+237,798
+28% +$4.93M ﹤0.01% 1952
2017
Q3 		$15.5M Buy
854,018
+407,703
+91% +$6.36M ﹤0.01% 2192
2017
Q2 		$6.91M Buy
446,315
+165,342
+59% +$2.49M ﹤0.01% 2579
2017
Q1 		$4.85M Buy
280,973
+5,490
+2% +$72.3K ﹤0.01% 2709
2016
Q4 		$3.03M Buy
275,483
+4,596
+2% +$55.7K ﹤0.01% 2930
2016
Q3 		$4.25M Buy
270,887
+16,386
+6% +$198K ﹤0.01% 2646
2016
Q2 		$2.6M Buy
254,501
+162,724
+177% +$1.86M ﹤0.01% 2926
2016
Q1 		$1.18M Buy
91,777
+23,698
+35% +$329K ﹤0.01% 3178
2015
Q4 		$1.42M Buy
+68,079
New +$1.08M ﹤0.01% 3113

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street's CTMX Position: Q1 2026 in Review

State Street increased its CytomX Therapeutics (CTMX) stake by 10% in Q1 2026, buying an estimated $2.65M and bringing the position to 5,663,408 shares worth $26.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2092.

State Street first reported a position in CTMX in Q4 2015 and has held it in 42 quarters since. The position peaked at $39.1M in Q2 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • State Street held 5,663,408 shares of CytomX Therapeutics worth $26.6M as of Q1 2026.
  • State Street bought 522,477 CytomX Therapeutics shares in Q1 2026, an estimated $2.65M.
  • CytomX Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #2092 holding.
  • State Street first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 42 quarters since.
  • State Street's CytomX Therapeutics position peaked at $39.1M in Q2 2018.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.